Business Context and Reporting Period
Company: Oragenics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 9, 2015
Event: Entry into a Material Definitive Agreement with Intrexon Corporation and Intrexon Actobiotics NV.
Oragenics entered into a worldwide Exclusive Channel Collaboration Agreement (ECC) to research, develop, and commercialize products using Intrexon's proprietary technology for genetically modified bacteria. The program focuses on the treatment of oral mucositis (specifically product AG013) and other conditions of the oral cavity, throat, and esophagus, excluding anti-cancer effector delivery.
Key Financial Metrics and Obligations
This filing details contractual obligations rather than historical financial performance. No revenue, profit, or cash flow data for the reporting period is provided in this document.
- Technology Access Fee: $5,000,000 paid via a Convertible Promissory Note (maturity: December 31, 2015).
- Revenue Share: Oragenics will pay Intrexon 12% of net sales from products developed under the collaboration.
- Commercialization Milestones (Payable in Stock or Cash):
- Phase II Milestone (First dosing): $2,000,000 per product.
- Phase IIb/III Milestone (Primary endpoint met): $5,000,000 per product.
- Regulatory Approval Application Milestone (NDA/BLA filing): $5,000,000 per product.
- Approval Milestone (First commercial sale or 90 days post-approval): $10,000,000 per product.
- New Indication Milestone (Supplemental application for AG013): $5,000,000.
- New Product Milestone (Regulatory package for different drug product): $5,000,000.
Material Changes and Agreements
The primary material change is the execution of the ECC and a concurrent Stock Issuance Agreement (SIA). Key terms include:
- Licensing: Oragenics received an exclusive worldwide license to Intrexon's technology and existing regulatory data for AG013.
- Responsibilities: Oragenics funds development, clinical trials, and commercialization. Intrexon handles technology discovery and cell-engineering.
- Convertible Note Terms: The $5 million note is payable at Oragenics' option in cash or common stock. Conversion requires shareholder approval. The conversion price equals the closing stock price on the last trading day prior to conversion.
- Standstill Provision: Intrexon agreed to a three-year standstill, restricting it from seeking control, initiating acquisitions, or soliciting proxies without Oragenics' invitation.
Outlook, Risks, and Contingencies
- Payment Flexibility: If issuing stock for milestones would cause Intrexon to consolidate Oragenics' financial statements, Oragenics may pay in cash. If cash payment adversely affects working capital, it may be structured as an interest-bearing promissory note with a maturity of less than 12 months.
- Termination Rights: Oragenics may terminate the agreement with 90 days' written notice. Intrexon may terminate for uncured breaches or failure to pursue a "Superior Therapy."
- Post-Termination Rights: Upon termination, Oragenics may continue developing products that are already generating profit sharing, have regulatory approval, are pending approval, or are in clinical trials (specifically AG013 with completed Phase II or other products in Phase I-III).
- Company Sale: If Oragenics is sold before milestone payments are made, subsequent payments become payable only in cash.
Investor Verification Checklist
- Verify the status of shareholder approval required to convert the $5 million note into common stock.
- Confirm the current development status of AG013 and the timeline for the Phase II clinical trial to trigger the $2 million milestone.
- Review the full text of the Exclusive Channel Collaboration Agreement (Exhibit 10.1) for redacted confidential terms.
- Assess the impact of the 12% net sales royalty on future gross margins for commercialized products.
- Monitor the company's working capital position to determine if future milestone payments will require cash or promissory notes.